Financial Performance - Total revenues for the three months ended June 30, 2024, were $694,270, a decrease of 7.9% compared to $753,649 for the same period in 2023[5] - Net income for the same period was $35,327, down 26.0% from $47,724 in the prior year[5] - Earnings per share attributable to shareholders decreased to $0.36 from $0.50, reflecting a decline of 28.0%[5] - Comprehensive income for the three months ended June 30, 2024, was $46,028, compared to $33,167 in the same period last year, reflecting a growth of 38.6%[7] - Revenue from construction contracts was $394,993, down 22.4% from $508,868 in the prior year[75] - Life Sciences market revenue increased to $328,421, up 15.2% from $284,970 in the previous year[76] - The company reported net finance costs of $19,518 for the three months ended June 30, 2024, compared to $16,946 in the same period last year[79] Assets and Liabilities - Total assets increased to $4,242,282 as of June 30, 2024, compared to $4,088,799 as of March 31, 2024, representing a growth of 3.8%[3] - Total liabilities increased to $2,554,727, compared to $2,404,852, marking a rise of 6.2%[3] - Long-term debt rose to $1,289,758 from $1,171,796, an increase of 10.0%[3] - Trade receivables as of June 30, 2024, were $538,689, an increase from $437,329 as of March 31, 2024[76] - Contract assets rose to $726,427 from $704,703, while contract liabilities increased to $365,359 from $312,204[76] Cash Flow and Equity - Cash and cash equivalents rose to $185,086 from $170,177, an increase of 8.3%[3] - Cash flows used in operating activities for the three months ended July 2, 2023, were $(107,796), while cash flows provided by financing activities were $92,375[14] - The company reported total equity of $1,529,454 as of July 2, 2023, up from $1,130,583 as of March 31, 2023[11] - Cash and cash equivalents at the end of the period were $123,520, down from $159,867 at the beginning of the period[14] Shareholder Activities - The company repurchased 1,020,887 common shares for $44,983 during the three months ended June 30, 2024, with a total of 7,023,631 shares remaining available for repurchase under the NCIB program[49] - The authorized share capital consists of an unlimited number of common shares, and the company intends to purchase up to 8,044,818 common shares under the normal course issuer bid (NCIB) by December 14, 2024[48] - The total number of common shares outstanding decreased from 98,219,496 on March 31, 2024, to 97,200,364 on June 30, 2024, reflecting a repurchase of shares[50] - The weighted average number of common shares outstanding increased to 98,119,205 from 94,397,253 year-over-year[82] Expenses and Costs - The company recognized an income tax expense of $12,748 for the three months ended June 30, 2024, compared to $14,380 for the same period in the previous year[54] - The company recognized a tax expense related to Pillar Two income taxes of $513 during the three months ended June 30, 2024[54] - The company recognized an expense of $837 related to short-term and low-value leases in the cost of revenues for the three months ended June 30, 2024, down from $1,001 in the same period last year[31] - The company reported a total stock-based compensation expense of $3,723 for the three months ended June 30, 2024, down from $9,990 in the same period last year[67] Acquisitions and Future Plans - The company acquired Paxiom Group for cash consideration of $140,000, with the transaction closing on July 24, 2024[24] - The company expects to close the acquisition of Heidolph Instruments in the third calendar quarter of 2024, subject to closing conditions[25] - The company plans to reduce its cost structure in response to a slowdown in the North American EV market, with estimated costs of $15 million to $20 million expected to commence in the second quarter of fiscal 2025[38] Currency and Risk Management - The company reported a currency translation adjustment of $11,393, compared to a loss of $20,227 in the prior year[7] - The company recorded risk management losses of $1,310 on foreign currency risk management forward contracts for the three months ended June 30, 2024, compared to gains of $6,636 in the prior year[36] Working Capital - Total change in non-cash working capital was a decrease of $106,874 for the three months ended June 30, 2024, compared to a decrease of $184,454 in the prior year[84] - The company reported a change in non-cash operating working capital of $(184,454) for the three months ended July 2, 2023[14] - As of June 30, 2024, the total balance of right-of-use assets increased to $108,044, up from $105,661 as of March 31, 2024, reflecting an addition of $9,929 during the quarter[29] - Lease liabilities rose to $114,309 as of June 30, 2024, compared to $111,379 at the end of March 2024, with additions of $9,929 and interest of $1,420 recorded[30] Minimum Purchase Obligations - The minimum purchase obligations as of June 30, 2024, totaled $350,163, with $337,299 due within one year[68]

Core Viewpoint - ATS is expected to report a year-over-year decline in earnings due to lower revenues, with the earnings report set for August 8, 2024, being a significant factor for stock price movement [1] Group 1: Earnings Estimates - ATS is projected to post quarterly earnings of $0.40 per share, reflecting a year-over-year decrease of 21.6% [2] - Revenues for ATS are anticipated to be $507.18 million, down 9.6% from the same quarter last year [2] Group 2: Estimate Revisions - The consensus EPS estimate for ATS has been revised down by 0.61% over the last 30 days, indicating a bearish sentiment among analysts [3] - The Most Accurate Estimate for ATS is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -6.33% [6] Group 3: Earnings Surprise Prediction - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [5] - ATS currently holds a Zacks Rank of 4, making it challenging to predict an earnings beat [7] Group 4: Historical Performance - In the last reported quarter, ATS had an earnings surprise of +17.07%, with actual earnings of $0.48 per share compared to an expected $0.41 [8] - Over the past four quarters, ATS has beaten consensus EPS estimates two times [8] Group 5: Industry Comparison - Helios Technologies, another player in the same industry, is expected to report earnings of $0.61 per share, indicating a year-over-year decline of 24.7% [10] - Helios Technologies has a Zacks Rank of 5, making it difficult to predict an earnings beat, despite a recent revision of the EPS estimate being 0.8% higher [10]

 Neumifil delivers statistically significant reductions in influenza symptomatic infection rate, symptom severity and viral loadStrategy to advance clinical development of Neumifil to be based on these positive data and pre-clinical data package demonstrating Neumifil’s activity against a broad range of viruses St Andrews, UK – 23nd May 2024 - Pneumagen, a clinical stage biotech company developing Neumifil (HEX17), a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respir ...

KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting Additional KT-621 preclinical data was also featured in a poster presentation at Digestive Disease Week KT-621 expected to start Phase 1 in the second half of 2024,with Phase 1 data in the first half of 2025 WATERTOWN, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage bio ...

JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held from May 17-22, 2024 in San Diego. InflaRx is presenting a poster at the thematic poster session at the ATS conference today from 11:30 AM PT / 2:30 PM ET to 1:15 PM PT / 4:15 PM ET. The poster is titled, “Vilobelima ...

Core Insights - The NOTUS phase 3 study confirms Dupixent's efficacy in reducing COPD exacerbations by 34% and improving lung function, marking it as a potential first new treatment for COPD in over a decade [1][2][3] Study Results - Dupixent significantly reduced moderate or severe COPD exacerbations by 34% over 52 weeks compared to placebo (p<0.001), meeting the primary endpoint [2][3] - Patients on Dupixent showed more than two times greater improvement in lung function (pre-bronchodilator FEV1) at 12 weeks (139 mL vs. 57 mL; p<0.001) and maintained improvement at week 52 (115 mL vs. 54 mL; p=0.018) [2][3] - Health-related quality of life improvements and reductions in respiratory symptom severity were also observed, although these were numerically greater rather than statistically significant [2] Safety Profile - The overall rates of adverse events (AEs) were similar between Dupixent (67%) and placebo (66%) [3] - Common AEs for Dupixent included COVID-19 (9.4%), nasopharyngitis (6.2%), and headache (7.5%), while COPD-related AEs were more common in the placebo group (7.8%) [3] Regulatory Status - Dupixent is under Priority Review by the US FDA for use in uncontrolled COPD with type 2 inflammation, with a target action date of June 27, 2024 [3] - Regulatory submissions are also under review in the EU and China, with ongoing discussions with other regulatory authorities [3] Background on COPD - COPD is a progressive respiratory disease with significant health and economic burdens, affecting approximately 300,000 people in the US with uncontrolled symptoms and type 2 inflammation [5]

NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD TARRYTOWN, N.Y. and PARIS, May 20, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: ...

Late-Breaking Results From the Phase 2a COURSE Trial Illustrate Tezspire's Impact on COPD Exacerbations in Patients With a Broad Range of Eosinophil Levels THOUSAND OAKS, Calif., May 19, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, ...

SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- When:          May 17–22, 2024Where:         San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101                       Marriott Marquis San Diego Marina | 333 West Harbor Dr. San Diego, CA 92101Research:     26 ResMed-supported abstracts will be presented at ATS. Full list below. Highlights:Innovation Hub:     Healthcare of Today, Looking Towards Tomorrow: Digital Innovations and Patient CentricityBooth #1442:            Featuring ResMed’s late ...

Financial Performance - Revenues for Q4 2024 increased 8.3% year over year to $791.5 million, with a year-to-date revenue increase of 17.7% to $3,032.9 million[3][4]. - Net income for Q4 2024 was $48.5 million, a 63.9% increase from $29.6 million in Q4 2023, while year-to-date net income rose 52.1% to $194.2 million[3][4]. - Adjusted EBITDA for Q4 2024 was $115.8 million, a 2.0% decrease from $118.2 million a year ago, with year-to-date adjusted EBITDA increasing 17.3% to $470.6 million[3][4]. - Total revenues for fiscal 2024 were reported at $3,032.9 million, a 17.6% increase from $2,577.4 million in fiscal 2023[59]. - Adjusted EBITDA for fiscal 2024 was $470.6 million, compared to $401.2 million in fiscal 2023, reflecting a year-over-year increase of approximately 17.3%[39]. - Net income for the fiscal year 2024 was $194.2 million, a significant increase of 52.1% from $127.7 million in fiscal 2023[59]. - Earnings from operations for Q4 2024 were $74.8 million, up from $51.9 million in Q4 2023, representing a year-over-year increase of approximately 43%[38]. - The company reported a basic EPS of $0.49 for Q4 2024, compared to $0.32 for Q4 2023, representing an increase of 53.1%[44]. - Earnings per share attributable to shareholders increased to $1.98 for fiscal 2024, up from $1.39 in fiscal 2023, representing a growth of 42.4%[59]. Order Bookings and Backlog - Order Bookings for Q4 2024 were $791 million, a 7.3% increase year over year, while year-to-date Order Bookings totaled $2,891 million, down 11.2% from the previous year[3][4][16]. - Order Backlog at the end of Q4 2024 was $1,793 million, a decrease of 16.7% compared to $2,153 million at the end of Q4 2023[6][18]. - The Order Backlog stands at $1,793 million, with an expected revenue conversion rate of 36% to 40% in Q1 fiscal 2025[22]. - Approximately $200 million of Order Backlog related to an EV customer was delayed, with a reduction of $50 million in the fourth quarter due to scope changes[22]. - Total order backlog as of March 31, 2024, is $1,793 million, down from $2,153 million in the previous year, representing a decrease of 16.7%[40]. - Total order bookings for the fiscal year 2024 amount to $2,891 million, a decline of 11.2% from $3,256 million in fiscal year 2023[41]. Acquisitions and Strategic Focus - The company announced the acquisition of Paxiom Group, expected to close in Q3 2024, enhancing its packaging solutions portfolio[7]. - The company acquired IT.ACA on January 1, 2024, strengthening its automation system integration capabilities in southern Europe[8]. - The company aims to achieve organic revenue growth and identify strategic acquisition opportunities to access attractive end-markets[23]. - The company anticipates future growth through organic expansion and acquisitions, with a focus on emerging markets and digitalization capabilities[69]. Market Trends and Challenges - The life sciences market remains strong, with expected revenues from GLP-1 drugs projected to become a high single-digit percentage of total revenues in the coming years[19]. - Customers are exercising caution in investment and spending, but underlying trends such as rising labor costs and production reshoring remain favorable for the company's solutions[21]. - The company is focused on clean energy applications, including solutions for nuclear power plant refurbishment and grid battery storage[20][21]. - There are concerns regarding the impact of macroeconomic factors such as inflation, supply chain disruptions, and interest rate changes on the company's operations[70]. - The company acknowledges risks related to customer concentration and potential impacts from regional or global conflicts on market performance[71]. - The company is facing challenges in securing labor and materials, which may affect its ability to expand operations organically or through acquisitions[71]. - There is uncertainty regarding the conversion of sales funnel to order bookings due to competitive factors and customer needs[72]. - The company is monitoring the potential impact of changes in accounting standards on its financial statements[73]. Financial Position and Cash Flow - Cash and cash equivalents increased to $170.2 million as of March 31, 2024, compared to $159.9 million in the previous year, representing a growth of 8.1%[50]. - Free cash flow for Q4 2024 was $(16.3) million, a decrease from $47.9 million in Q4 2023, reflecting a decline of 134.0%[51]. - Cash flows provided by operating activities decreased significantly to $20,780 from $127,800, a decline of 83.8%[61]. - Cash flows used in investing activities increased to $(341,785) from $(109,022), representing a rise of 213.5%[61]. - Cash flows provided by financing activities surged to $330,724 from $4,882, an increase of 6,635.5%[61]. - The company reported cash income taxes paid of $49,511, down from $58,398, a decrease of 15.9%[61]. - The company’s total bank indebtedness decreased to $(1,527) from $3,399, indicating improved financial leverage[61]. - The net debt to adjusted EBITDA ratio improved to 2.4x as of March 31, 2024, down from 2.7x in the previous year[50]. - The company reported a debt-to-equity ratio of 0.79:1 as of March 31, 2024, improved from 1.18:1 in the previous year[55]. - The company’s long-term debt stood at $1,171.8 million as of March 31, 2024, slightly up from $1,155.7 million in the previous year[50]. - Non-cash working capital as a percentage of trailing six-month revenues increased to 19.0% as of March 31, 2024, compared to 10.1% in the previous year[49]. - Non-cash working capital levels as a percentage of revenues may fluctuate due to timing and nature of order bookings and payment terms[72].